Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Autoimmune, and Tissue-Regenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSG-6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSG-6 (TNFAIP6) ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TSG-6 Products |
| Gene Delivery | TSG-6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TSG-6 Products |
| Benchmark Ab | Anti-TSG-6 Recombinant Antibody Recombinant positive control. |
View TSG-6 Products |
| Validator | TSG-6 siRNA Set For knockdown verification. |
View TSG-6 Products |
| Related Target A | CD44 Primary cell-surface receptor mediating HA-TSG-6 complex signaling. |
View CD44 Products |
| Related Target B | TNF-alpha Primary upstream inducer of TSG-6 expression in inflammatory microenvironments. |
View TNF-alpha Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Validating functional Hyaluronan (HA) binding activity | HEK293 expressed recombinant TSG-6 preserving native glycosylation and Link-domain disulfide conformation. |
| Assaying Heavy Chain (HC) transfer from IαI to HA | Highly purified, sequence-verified TSG-6 ensuring enzymatic-like transesterification activity in vitro. |
| Lack of standardized positive controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Off-target cross-reactivity with other Link-module proteins | Homolog screening panel (including Aggrecan and Versican) strictly verified by mass spectrometry. |
Live TSG-6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of TSG-6 (Tumor Necrosis Factor-Inducible Gene 6 Protein) is expanding rapidly, transitioning from its historical identity as a mere inflammatory biomarker to a potent, multi-functional biotherapeutic agent. Primarily recognized as a key mediator of mesenchymal stem cell (MSC)-induced immunomodulation, TSG-6 is being actively developed as a recombinant protein therapeutic to resolve pathological inflammation and promote tissue repair.
The race for TSG-6 therapeutics is intensifying, with major players shifting focus from traditional mAbs to recombinant protein optimization and gene-modified cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized delivery systems, such as intra-articular injections for osteoarthritis and topical ophthalmic formulations for dry eye disease, to maximize local anti-inflammatory efficacy while minimizing systemic exposure.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | Anika Therapeutics, Academic Spin-offs | Dry Eye Disease, Osteoarthritis, Myocardial Infarction | HA-binding & CD44 interaction assays (Requires native HEK293 glycosylated TSG-6) |
| Cell Therapy (MSC-derived) | Mesoblast, Athersys | GvHD, Acute Lung Injury, ARDS | Potency & Identity validation (Requires high-specificity TSG-6 siRNA & antibodies) |
| Gene Therapy / Vector | Biopharma Research Institutes | Rheumatoid Arthritis, Cornea Injury | Overexpression verification (Requires high-titer Lentivirus for stable cell lines) |